1 / 30

SCID SCREENING: A NEW YORK STATE OF MIND

New York Newborn Screening Program - DNA. SCID SCREENING: A NEW YORK STATE OF MIND. Jason Isabelle June 4-5, 2012. What is SCID?. S evere C ombined I mmuno d eficiency Caused by diverse mutations in several different genes resulting in a combined immune deficiency

sanam
Download Presentation

SCID SCREENING: A NEW YORK STATE OF MIND

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. New York Newborn Screening Program - DNA SCID SCREENING: A NEW YORK STATE OF MIND Jason Isabelle June 4-5, 2012

  2. What is SCID? • Severe Combined Immunodeficiency • Caused by diverse mutations in several different genes resulting in a combined immune deficiency • X-Linked/Autosomal Recessive Inheritance • Prevalence: ~1:40,000-100,000 • 3-7 affected newborns in NY each year • Extreme lack of T lymphocyte differentiation and function • Severally impaired humoral/cellular immunity • Often fatal within the first year of life Prepared by Jason Isabelle-NYSNSP

  3. SCID Classification • X-linked SCID • Mutations in the gene encoding the common gamma chain of IL-2,4,7, & 9 cytokine+ receptors • Autosomal Recessive SCID • Adenosine deaminase deficiency • Jak3 tyrosine kinase deficiency • RAG1,2 • IL-7R (α chain) • CD-45 David Vetter: X-linked SCID

  4. Treatment Methods • Allogeneic hematopoietic stem cell transplant (HSCT) • Donor marrow is depleted of T cells (Prevents GVHD) • Allows for half-matched donor • Climbing to a 90% success rate if administered <3 months of age • Enzyme replacement therapy • ADA deficient SCID • Gene Therapy • X-linked or ADA deficient SCID

  5. T Cell Receptor Excision Circles • By-products of T cell receptor gene rearrangements during T cell maturation in the thymus • TRECs do not replicate during mitosis • Episomal DNA that gets diluted by cell divisions • TREC levels in peripheral blood reflect T cell production in the thymus • Low/No TRECs = Low/No T cell production by the thymus

  6. δRec-ψJα TREC Is Ideal • Created from the sequential rearrangements of the TCR α/δ locus • 70% of thymocytes that express α/β TCR will form this specific TREC • Signal joint region of this TREC is flanked by a conserved region • Allows for universal primer design that will always detect this TREC • Occurs late in maturation • Likely to generate a functional and diverse T cell repertoire

  7. Sequential Rearrangements of the TCRAD Locus Hazenberg MD, Verschuren MCM,Hamann D, Miedema F, van Dongen JMJ (2001) T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. J Mol Med 79:631-640 Prepared by Jason Isabelle-NYSNSP

  8. History of SCID Testing • Automated assay developed and validated 12/2009-9/2010 • Submitted validation package to NYS Clinical Laboratory Evaluation Program (CLEP) for approval on 9/08/2010 • CLEP and emergency regulation approved 9/27/2010 • SCID screening started 9/29/2010 • 1st “True SCID” baby detected 12/27/2010 (NICHD Support) • Presumptive Positive (Borderline) category added 1/25/2011 • Commissioner of Health officially adds SCID to NSP panel 4/12/2011

  9. DNA Extraction Fast Facts • CASM ‘Homebrew’ Extraction • 4 Solutions • 100μl Total Volume • Tip Intensive • Easily Scalable • Low-Mid Throughput • Average Yield: 4-5ng/μl

  10. DNA Extraction Components • RBC Lysis Solution • Targets and destroys known PCR inhibitors • Immunoglobulins, hemoglobin, etc • Wash Solution • Eliminate lysis by-products • Buffer A • Lyses of WBC’s and “scratches” fiber matrix • Buffer B • Neutralize pH and solubilize DNA

  11. Why Automate? • Accommodate increased throughput • Reduce repetitive stress injuries • Address staffing shortages • Increase reproducibility and consistency of results

  12. Automation Obstacles • Many manual processes are difficult to automate • Centrifugation, heating/cooling, vortexing, etc… • Spot/Tip interactions • 10….960….3,840….11,520

  13. Automated Method Development • Labware Adjustments • Liquid Type Editor • Pipetting Template • Volume Conditioning METHOD CREATION

  14. Liquid Handling System Each complete Liquid Handling System is capable of 1200 DNA extractions per 8 hour day.

  15. Liquid Handling Components Each Shaking Peltier Device can heat/cool from +4°C to +70°C . Each Cytomat has a capacity of 6048 Tips when fully loaded.

  16. SCID Assay • 10 μl Final Volume • (8μl Reaction Mix/2μl DNA) • RNaseP/TREC Multiplex • 8-Point Standard Curve In Triplicate • 2000,1000,500,250,125,62.5,31.2,15.6 Copies • +SCID/-SCID Control In Triplicate • ADA, IL7R alpha, X-Linked, Omenn’s Syndrome—0 Avg • Cutoff: 200 Trecs/μl of Whole Blood

  17. Taqman Chemistry • Reporter/Quencher • 5’ Nuclease Activity • Probe Cleavage • Sequence Specific • Multiplex Capability Applied Biosystems

  18. TREC Assay PCR Product 62bp amplicon Probe sequence spans signal joint

  19. Beckman Biomek NX 96 Well Extraction Plate to 384 Well Reaction Plate. Shaking-Heating-Multiplate Adapters

  20. Applied Biosystem 7900HT Each 7900HT is capable of running 1500 samples per 8 hour day.

  21. Absolute Quantification Run

  22. Data Analysis QPCR Terms • Baseline Adjustment • Threshold Adjustment • Algorithm Settings • Individual Trace Analysis Sample Passes Applied Biosystems

  23. “Typical” Amplification Curve

  24. Amplification Curve: Fail!

  25. ADA Deficient SCID • 2nd most common form of SCID • ~15% of all SCID cases • Autosomal recessive inheritance • Mutations in the ADA gene reduce or eliminate the activity of the enzyme adenosine deaminase • Toxic buildup of deoxyadenosine ensues • Massive reduction in lymphocyte population • Affected newborns have options

  26. ADA-SCID Absolute Quantification Run ADA RNaseP TREC

  27. Duplex Amplification Plots TREC Amplification plot Rnase p amplification plot ADA ADA

  28. NY-NBS SCID Algorithm Multiplex PCR (TREC/RNaseP) TREC values are copies/ul RNaseP values are Cq Dried Blood Spot Specimen TREC ≥ 200 and RNase P < WAL TREC< 200 Sample is retested in duplicate RNase P ≥ 35 SCREEN NEGATIVE Two of Three RNaseP WAL AND Two of Three TREC ≤200 AND Gestation Age ≥37 AND Average of Three TREC ≤200 if a previous PP OR Average of Three TREC <150 if an initial Specimen Two of Three RNaseP WAL AND Two of Three TREC ≥ 200 OR Average of Three TREC ≥200 Two of Three RNaseP WAL AND Two of Three TREC < 200 AND Average of Three TREC >125<200 AND Gestation Age ≥37 AND Has never been a PP before Two of Three RNaseP WAL AND Two of Three TREC <200 AND Average of Three TREC <200 AND Gestation Age <37 SCREEN NEGATIVE PRESUMPTIVE POSITIVE REPEAT PREMATURE REFERRAL

  29. Conclusion • Early detection benefits • Adaptable screening methodology • Prevalence • Treatment • Testing

  30. Funding Support The New York State Department of Health The Eunice Kennedy Shriver Institute for Child Health and Human Development Jeffrey Modell Foundation

More Related